Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 137
interventional 103
Observational 24
Registry 10

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 54
Drug|placebo 15
Other 8
Biological 4
Biological|placebo 3
Dietary Supplement|Drug 3
Procedure 3
Diagnostic Test 2
Dietary Supplement 2
Drug|Procedure|Radiation 2
Behavioral 1
Behavioral|Device|Other 1
Device 1
Dietary Supplement|Other 1
Drug|Other 1
Drug|Procedure 1
Radiation 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
South Africa 21
United States 9
India 7
China 5
NA 4
Brazil 3
Korea, Republic of 3
South Africa|Tanzania 3
Tanzania 3
Bangladesh 2
Ethiopia 2
Indonesia 2
Malawi 2
Switzerland 2
Belarus|South Africa|Uzbekistan 1
Belgium 1
Botswana|Guinea|Mexico|Nepal|Pakistan|Peru|Uganda 1
Brazil|Georgia|Malaysia|Philippines|Russian Federation|South Africa|Tanzania|Uganda 1
China|India|Kenya|Malaysia|Mexico|South Africa|Tanzania|Thailand|Zambia 1
China|South Africa 1
Colombia 1
France 1
Georgia|India|Kazakhstan|Lesotho|Pakistan|Peru|South Africa 1
Georgia|Kenya|Malaysia|Philippines|South Africa|Tanzania|Uganda|Zambia 1
Georgia|Moldova, Republic of|Russian Federation|South Africa 1
Germany 1
Ghana 1
Guinea-Bissau 1
Indonesia|Peru|Romania 1
Indonesia|Philippines|Singapore|Thailand 1
Japan 1
Netherlands 1
Pakistan 1
Peru|South Africa 1
Peru|Vietnam 1
Philippines|Singapore|Uganda 1
Russian Federation 1
Singapore 1
South Africa|Tanzania|Uganda 1
Taiwan 1
Uganda 1
United Kingdom 1
United States|Brazil 1
United States|Brazil|Canada|South Africa|Spain|Uganda 1
United States|Canada 1
United States|Canada|South Africa|Uganda 1
United States|China|Egypt|Estonia|Japan|Korea, Republic of|Latvia|Peru|Philippines 1
United States|South Africa|Uganda 1
Zambia 1

Sites per Study

Site_count Study_Count
1 52
2 15
3 7
4 4
5 1
6 3
7 3
8 2
9 1
10 3
11 1
12 1
14 1
17 1
20 1
21 1
23 2
26 2
29 1
47 1

Phase

Phase Study_Count
Phase 2 41
N/A 21
Phase 3 18
Phase 1 11
Phase 4 5
Phase 1/Phase 2 4
Phase 2/Phase 3 3

Number of Arms

Number_of_Arms Count_of_Studies
1 6
2 34
3 15
4 11
5 8
6 9
7 1
8 4
9 1
10 2
12 1
13 1
19 1
NA 9

Enrollment Metrics by Phase

Measure N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 24.000 30.00000 31.00 24.0000 455.0000 109.0000 100.0
1st Qu. 160.000 32.00000 60.25 58.0000 542.5000 258.5000 172.0
Median 264.000 44.00000 73.50 88.0000 630.0000 528.5000 300.0
Mean 1207.333 49.63636 75.75 196.1951 661.6667 636.0556 7250.8
3rd Qu. 572.000 63.00000 89.00 240.0000 765.0000 950.0000 924.0
Max. 11337.000 91.00000 125.00 1200.0000 900.0000 1931.0000 34758.0

Trial Group Type

group_type Group_Count
Experimental 212
Active Comparator 87
Placebo Comparator 50
No Intervention 11
NA 9
Other 8
Sham Comparator 1

Intervention Model

intervention_model Study_Count
Parallel Assignment 76
Single Group Assignment 9
Sequential Assignment 8
Factorial Assignment 5
NA 4
Crossover Assignment 1

Primary Purpose

primary_purpose Study_Count
Treatment 81
Diagnostic 10
Prevention 5
Supportive Care 3
Health Services Research 2
Other 1
NA 1

Observational Studies

Studies by Country

Country Study_Count
Korea, Republic of 3
United States 3
India 2
Taiwan 2
Belarus|Georgia|India|South Africa 1
Brazil 1
China 1
Ethiopia 1
Ethiopia|Gambia|Germany|Namibia|Netherlands|South Africa|Uganda|United Kingdom 1
Ethiopia|India 1
Hong Kong 1
Indonesia 1
Italy 1
Mali 1
Moldova, Republic of 1
NA 1
Peru 1
Romania 1

Sites per Study

Site_count Study_Count
1 16
2 2
3 1
4 1
6 1
10 2
20 1

Enrollment Metrics

Measure Observational
Min 10.0000
1st Qu 55.0000
Median 318.0000
Mean 438.3043
3rd Qu 680.0000
Max 1666.0000

Observation Model

observational_model Study_Count
Cohort 9
Case-Only 5
Case-Control 3
NA 3
Case Control 2
Other 2

Time Perspective

time_perspective Study_Count
Prospective 16
Cross-Sectional 6
Other 1
Retrospective 1

Registries

Studies by Country

Country Study_Count
Korea, Republic of 3
China 1
France 1
Gambia|Mozambique|South Africa|Tanzania 1
Georgia 1
Italy 1
NA 1
Netherlands 1

Sites per Study

Site_count Study_Count
1 8
3 1
4 1

Enrollment Metrics

Measure Registries
Min 8.00
1st Qu 91.75
Median 224.50
Mean 440.90
3rd Qu 725.00
Max 1600.00

Registry Model

observational_model Study_Count
Cohort 7
Case-Only 1
Case Control 1
Other 1

Time Perspective

time_perspective Study_Count
Prospective 9
Other 1

Follow-up

target_duration Study_Count
2 Months 2
2 Years 2
6 Months 2
1 Week 1
10 Years 1
12 Months 1
8 Years 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT03338621 Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients https://ClinicalTrials.gov/show/NCT03338621 Active, not recruiting Global Alliance for TB Drug Development 2020-04-30
NCT03302949 Treating Tuberculosis Wasting With a High-protein Supplement https://ClinicalTrials.gov/show/NCT03302949 Active, not recruiting University of Aarhus 2020-08-31
NCT03281226 RIPE vs RIPE Plus N-acetylcysteine in Patients With HIV/TB Co-infection https://ClinicalTrials.gov/show/NCT03281226 Recruiting Fundação de Medicina Tropical Dr. Heitor Vieira Dourado 2019-06-30
NCT03199339 A Phase 1 Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371 https://ClinicalTrials.gov/show/NCT03199339 Completed Global Alliance for TB Drug Development 2018-07-08
NCT03199313 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid https://ClinicalTrials.gov/show/NCT03199313 Completed Global Alliance for TB Drug Development 2017-12-16
NCT03174184 Early Bactericidal Activity of Rifampin + Meropenem + Amoxicillin/Clavulanate in Adults With Pulmonary TB https://ClinicalTrials.gov/show/NCT03174184 Recruiting Johns Hopkins University 2021-07-31
NCT03160638 Azithromycin as Host-directed Therapy for Pulmonary Tuberculosis https://ClinicalTrials.gov/show/NCT03160638 Recruiting University Medical Center Groningen 2020-02-01
NCT03086486 Safety and Efficacy of Various Doses and Treatment Durations of Linezolid Plus Bedaquiline and Pretomanid in Participants With Pulmonary TB, XDR-TB, Pre- XDR-TB or Non-responsive/Intolerant MDR-TB (ZeNix) https://ClinicalTrials.gov/show/NCT03086486 Active, not recruiting Global Alliance for TB Drug Development 2020-12-31
NCT02961569 Comparison Between Two Strategies for the Diagnosis of TB https://ClinicalTrials.gov/show/NCT02961569 Completed Hopital Lariboisière 2017-04-30
NCT02912832 Prospective Assessment of TBDx Feasibility https://ClinicalTrials.gov/show/NCT02912832 Completed Foundation for Innovative New Diagnostics, Switzerland 2015-03-31
NCT02836483 A Phase II Clinical Study of LCB01-0371 to Evaluate the EBA, Safety and PK https://ClinicalTrials.gov/show/NCT02836483 Completed LegoChem Biosciences, Inc 2019-07-01
NCT02774993 Doxycycline in Human Pulmonary Tuberculosis https://ClinicalTrials.gov/show/NCT02774993 Completed National University Hospital, Singapore 2017-06-30
NCT02754765 Evaluating Newly Approved Drugs for Multidrug-resistant TB https://ClinicalTrials.gov/show/NCT02754765 Recruiting Médecins Sans Frontières, France 2020-09-30
NCT02589782 Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s) https://ClinicalTrials.gov/show/NCT02589782 Recruiting Medecins Sans Frontieres, Netherlands 2020-06-30
NCT02583048 Evaluating the Safety, Tolerability, and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, For Drug-Resistant Pulmonary Tuberculosis https://ClinicalTrials.gov/show/NCT02583048 Active, not recruiting National Institute of Allergy and Infectious Diseases (NIAID) 2019-01-07
NCT02581527 A Randomised Trial to Evaluate Toxicity and Efficacy of 1200mg and 1800mg Rifampicin for Pulmonary Tuberculosis https://ClinicalTrials.gov/show/NCT02581527 Recruiting St George’s, University of London 2021-01-31
NCT02558842 Intervention in the Management of Post-high Tuberculosis Hospital Through Educational Strategy and Oversight Distance https://ClinicalTrials.gov/show/NCT02558842 Completed Hospital de Clinicas de Porto Alegre 2015-09-30
NCT02554318 Fermented Soybean Supplementation Among Active Pulmonary Tuberculosis Patients With Standard Therapy in Indonesia https://ClinicalTrials.gov/show/NCT02554318 Completed University of Giessen 2015-02-28
NCT02481726 68Ga-AlfatideII for the Differential Diagnosis of of Lung Cancer and Lung Tuberculosis by PET/CT https://ClinicalTrials.gov/show/NCT02481726 Completed Xijing Hospital 2014-10-31
NCT02381470 Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers https://ClinicalTrials.gov/show/NCT02381470 Completed National University Hospital, Singapore 2019-09-28
NCT02371681 NexGen EBA Radiologic and Immunologic Biomarkers of Sterilizing Drug Activity in Tuberculosis https://ClinicalTrials.gov/show/NCT02371681 Completed National Institutes of Health Clinical Center (CC) 2017-09-01
NCT02349841 Phase 2 Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem Plus Amoxycillin/CA and Faropenem Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed Pulmonary Tuberculosis https://ClinicalTrials.gov/show/NCT02349841 Completed TASK Applied Science 2014-12-31
NCT02342886 Shortening Treatment by Advancing Novel Drugs https://ClinicalTrials.gov/show/NCT02342886 Completed Global Alliance for TB Drug Development 2018-01-31
NCT02333799 A Phase 3 Study Assessing the Safety and Efficacy of Bedaquiline Plus PA-824 Plus Linezolid in Subjects With Drug Resistant Pulmonary Tuberculosis https://ClinicalTrials.gov/show/NCT02333799 Active, not recruiting Global Alliance for TB Drug Development 2019-01-14
NCT02313610 Efficacy and Safety of Qinbudan as an Adjunct Therapy for Retreatment Pulmonary Tuberculosis https://ClinicalTrials.gov/show/NCT02313610 Completed Shanghai University of Traditional Chinese Medicine 2013-03-31
NCT02279875 A Phase 2 Trial to Evaluate the Efficacy and Safety of Linezolid in Tuberculosis Patients. (LIN-CL001) https://ClinicalTrials.gov/show/NCT02279875 Completed Global Alliance for TB Drug Development 2016-11-28
NCT02256696 Assessing PA-824 for Tuberculosis (the APT Trial) https://ClinicalTrials.gov/show/NCT02256696 Recruiting Johns Hopkins University 2020-09-30
NCT02219945 ENOSE in Pulmonary Tuberculosis in Yogyakarta https://ClinicalTrials.gov/show/NCT02219945 Completed University Medical Center Groningen 2014-12-31
NCT02193776 A Phase 2 to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis. https://ClinicalTrials.gov/show/NCT02193776 Completed Global Alliance for TB Drug Development 2016-02-08
NCT02153528 Optimization of the TB Treatment Regimen Cascade https://ClinicalTrials.gov/show/NCT02153528 Completed Damien Foundation 2017-08-01
NCT02106039 Pulmonary Tuberculosis Patients With Diabetes Mellitus https://ClinicalTrials.gov/show/NCT02106039 Completed Universitas Padjadjaran 2017-02-21
NCT02053129 Evaluation of PTB Screening in ANC in Lusaka, Zambia https://ClinicalTrials.gov/show/NCT02053129 Completed University of North Carolina, Chapel Hill 2012-10-31
NCT01927159 Phase 1 ID93 + GLA-SE Vaccine Trial in BCG-Vaccinated Healthy Adult Volunteers https://ClinicalTrials.gov/show/NCT01927159 Completed IDRI 2015-07-31
NCT01785186 Evaluation of SQ109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design https://ClinicalTrials.gov/show/NCT01785186 Completed Ludwig-Maximilians - University of Munich 2014-09-30
NCT01698476 Immune Reconstitution in Tuberculosis Disease https://ClinicalTrials.gov/show/NCT01698476 Completed Karolinska Institutet 2015-08-31
NCT01691534 Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z) https://ClinicalTrials.gov/show/NCT01691534 Completed Global Alliance for TB Drug Development 2013-04-30
NCT01618422 Directly Observed Therapy Short Course-Plus Versus DOTS for Retreatment of Relapsed Pulmonary Tuberculosis in Guangzhou https://ClinicalTrials.gov/show/NCT01618422 Completed Chinese University of Hong Kong 2013-02-28
NCT01599897 Phase 1 ID93 + GLA-SE Vaccine Trial in Healthy Adult Volunteers https://ClinicalTrials.gov/show/NCT01599897 Completed IDRI 2014-05-31
NCT01580007 Clinical Trial of Phenylbutyrate and Vitamin D in Tuberculosis (TB) https://ClinicalTrials.gov/show/NCT01580007 Completed International Centre for Diarrhoeal Disease Research, Bangladesh 2014-12-31
NCT01517022 Intensive Smoking-cessation Intervention Versus Smoking-cessation Advice in Smear-positive Patients With Pulmonary Tuberculosis https://ClinicalTrials.gov/show/NCT01517022 Completed All India Institute of Medical Sciences, New Delhi 2016-09-30
NCT01498419 Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB) (NC-002) https://ClinicalTrials.gov/show/NCT01498419 Completed Global Alliance for TB Drug Development 2013-04-30
NCT01392911 Safety, Tolerability, Extended Early Bactericidal Activity and PK of Higher Doses Rifampicin in Adults With Pulmonary TB https://ClinicalTrials.gov/show/NCT01392911 Completed Radboud University 2018-07-31
NCT01363765 Xpert MTB/Rif, a New Tool for the Diagnosis of Pulmonary Tuberculosis in Two Municipalities in Brazil https://ClinicalTrials.gov/show/NCT01363765 Completed Ataulpho de Paiva Foundation 2012-10-31
NCT04433195 Xpert MTB/RIF Test in the Diagnosis of Pulmonary Tuberculosis https://ClinicalTrials.gov/show/NCT04433195 Recruiting Taipei Medical University WanFang Hospital 2021-04-30
NCT04122404 POC Strategies to Improve TB Care in Advanced HIV Disease https://ClinicalTrials.gov/show/NCT04122404 Recruiting University of Southern Denmark 2021-08-15
NCT04044001 BTZ-043 - Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA) https://ClinicalTrials.gov/show/NCT04044001 Recruiting Ludwig-Maximilians - University of Munich 2020-10-31
NCT03967353 Study on the Management Model of “Home Treatment” for Tuberculosis Patients https://ClinicalTrials.gov/show/NCT03967353 Recruiting Beijing Chest Hospital 2022-03-31
NCT03882177 StAT-TB (Statin Adjunctive Therapy for TB): A Phase 2b Dose-finding Study of Pravastatin in Adults With Tuberculosis https://ClinicalTrials.gov/show/NCT03882177 Active, not recruiting National Institute of Allergy and Infectious Diseases (NIAID) 2020-12-31
NCT03851159 Nyaditum Resae® as a Co-adjuvant During Treatment for Active Pulmonary Tuberculosis and Its Impact on the Gut Microbiota https://ClinicalTrials.gov/show/NCT03851159 Recruiting University of Stellenbosch 2021-12-31
NCT03776500 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PBTZ169 in Multiple Dosing https://ClinicalTrials.gov/show/NCT03776500 Recruiting Innovative Medicines for Tuberculosis 2019-09-30
NCT03758612 A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adults https://ClinicalTrials.gov/show/NCT03758612 Completed Global Alliance for TB Drug Development 2020-03-14
NCT03702738 Adjunctive NAC in Adult Patients With Pulmonary Tuberculosis https://ClinicalTrials.gov/show/NCT03702738 Recruiting The Aurum Institute NPC 2020-10-30
NCT03678688 A Phase 1/2 Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis https://ClinicalTrials.gov/show/NCT03678688 Recruiting Otsuka Pharmaceutical Development & Commercialization, Inc. 2021-06-30
NCT03590600 A Single Ascending Dose Study of BTZ043 https://ClinicalTrials.gov/show/NCT03590600 Completed Ludwig-Maximilians - University of Munich 2018-08-14
NCT03561753 Pilot Clinical Trial of PRS TB Regimen I - Phase II https://ClinicalTrials.gov/show/NCT03561753 Enrolling by invitation Shanghai Pulmonary Hospital, Shanghai, China 2019-12-31
NCT03557281 An Early Bactericidal Activity, Safety and Tolerability of GSK3036656 in Subjects With Drug-sensitive Pulmonary Tuberculosis https://ClinicalTrials.gov/show/NCT03557281 Recruiting GlaxoSmithKline 2022-04-29
NCT03519425 A Pragmatic Randomised Study to Optimise Screening, Prevention and Care for Tuberculosis in Malawi https://ClinicalTrials.gov/show/NCT03519425 Active, not recruiting Liverpool School of Tropical Medicine 2019-12-31
NCT03512249 Study to Evaluate H56:IC31 in Preventing Rate of TB Recurrence https://ClinicalTrials.gov/show/NCT03512249 Recruiting Aeras 2022-04-06
NCT03478033 Rifampicin vs Rifabutin in HIV/AIDS Patients Combined With Tuberculosis https://ClinicalTrials.gov/show/NCT03478033 Recruiting Shanghai Public Health Clinical Center 2020-06-01
NCT03474198 Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis https://ClinicalTrials.gov/show/NCT03474198 Recruiting University College, London 2022-03-12
NCT03423030 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Ex-vivo Antitubercular Activity of PBTZ169 Formulation https://ClinicalTrials.gov/show/NCT03423030 Completed Innovative Medicines for Tuberculosis 2018-03-28
NCT01242592 Homeopathy as an Adjuvant to Chemotherapy Improves Clinical Outcome in Relapsed Pulmonary Tuberculosis https://ClinicalTrials.gov/show/NCT01242592 Completed NMP Medical Research Institute NA
NCT01218217 Early Bactericidal Activity (EBA) of SQ109 in Adult Subjects With Pulmonary TB https://ClinicalTrials.gov/show/NCT01218217 Completed Ludwig-Maximilians - University of Munich 2011-09-30
NCT01215851 Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z) (NC-001) https://ClinicalTrials.gov/show/NCT01215851 Completed Global Alliance for TB Drug Development 2011-05-31
NCT01215110 Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis (TMC207-CL001) https://ClinicalTrials.gov/show/NCT01215110 Completed Global Alliance for TB Drug Development 2010-08-31
NCT01162486 Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers https://ClinicalTrials.gov/show/NCT01162486 Completed Johns Hopkins University 2011-02-28
NCT01130311 Replacement of Vitamin D in Patients With Active Tuberculosis https://ClinicalTrials.gov/show/NCT01130311 Completed Aga Khan University 2010-04-30
NCT01043575 High Dose Rifapentine Pharmacokinetics, Tolerability and Safety Dosage Rifapentine for Treatment of Tuberculosis https://ClinicalTrials.gov/show/NCT01043575 Completed Centers for Disease Control and Prevention 2010-05-31
NCT01011543 Induced Sputum Versus Bronchoscopy in Smear Negative Pulmonary Tuberculosis https://ClinicalTrials.gov/show/NCT01011543 Completed Centre Hospitalier Universitaire Saint Pierre 2015-12-31
NCT00944021 Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis (CL-010) https://ClinicalTrials.gov/show/NCT00944021 Completed Global Alliance for TB Drug Development 2010-01-31
NCT00939419 The Effectiveness of Health Facility-based and Community-based Care for Tuberculosis https://ClinicalTrials.gov/show/NCT00939419 Completed University of Leeds 2006-12-31
NCT00933790 Comparing Daily vs Intermittent Regimen of ATT in HIV With Pulmonary Tuberculosis https://ClinicalTrials.gov/show/NCT00933790 Completed Tuberculosis Research Centre, India 2016-12-31
NCT00864383 Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis https://ClinicalTrials.gov/show/NCT00864383 Completed Global Alliance for TB Drug Development 2013-10-31
NCT02465216 Phase 2a ID93 + GLA-SE Vaccine Trial in TB Patients After Treatment Completion https://ClinicalTrials.gov/show/NCT02465216 Completed IDRI 2017-01-31
NCT00814671 Study of Daily Rifapentine for Pulmonary Tuberculosis https://ClinicalTrials.gov/show/NCT00814671 Completed Johns Hopkins University 2013-06-30
NCT01945905 Cost-effectiveness of Two Forms of DOTS in a Demonstration Area of the DOTS Strategy in Colombia https://ClinicalTrials.gov/show/NCT01945905 Completed Fundación FES 2014-08-31
NCT00801606 Micronutrient Supplementation in in Paediatric Pulmonary Tuberculosis https://ClinicalTrials.gov/show/NCT00801606 Completed All India Institute of Medical Sciences, New Delhi 2012-06-30
NCT03722472 Phase 1 Clinical Trial of Single-Vial ID93 + GLA-SE in Healthy Adults https://ClinicalTrials.gov/show/NCT03722472 Active, not recruiting IDRI 2020-03-31
NCT03044158 GeneXpert Performance Evaluation for Linkage to Tuberculosis Care https://ClinicalTrials.gov/show/NCT03044158 Active, not recruiting University of California, San Francisco 2020-03-01
NCT02821832 Using Biomarkers to Predict TB Treatment Duration https://ClinicalTrials.gov/show/NCT02821832 Recruiting National Institutes of Health Clinical Center (CC) 2021-12-31
NCT00760149 Pharmacokinetics and Pharmacodynamics of High Versus Standard Dose Rifampicin in Patients With Pulmonary Tuberculosis https://ClinicalTrials.gov/show/NCT00760149 Completed Radboud University 2013-09-30
NCT00727844 Linezolid to Treat Extensively-Drug Resistant Tuberculosis https://ClinicalTrials.gov/show/NCT00727844 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2012-10-31
NCT00694629 TBTC Study 29: Rifapentine During Intensive Phase Tuberculosis (TB) Treatment https://ClinicalTrials.gov/show/NCT00694629 Completed Centers for Disease Control and Prevention 2013-06-30
NCT00685360 A Placebo-controlled, Phase 2 Trial to Evaluate OPC 67683 in Patients With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB) https://ClinicalTrials.gov/show/NCT00685360 Completed Otsuka Pharmaceutical Development & Commercialization, Inc. 2010-06-30
NCT00677339 L-arginine and Vitamin D Adjunctive Therapy in Pulmonary Tuberculosis (TB) https://ClinicalTrials.gov/show/NCT00677339 Completed Menzies School of Health Research 2010-02-28
NCT00567840 PA-824-CL-007: Phase IIa Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis https://ClinicalTrials.gov/show/NCT00567840 Completed Global Alliance for TB Drug Development 2007-12-31
NCT00495339 MDR TB, Levofloxacin, Multi-Drug-Resistant Pulmonary Tuberculosis https://ClinicalTrials.gov/show/NCT00495339 Completed Sanofi 2008-04-30
NCT00425113 Metronidazole for Pulmonary Tuberculosis (South Korea) https://ClinicalTrials.gov/show/NCT00425113 Completed National Institutes of Health Clinical Center (CC) 2012-10-31
NCT00419068 Trial of Adjunctive Vitamin D in Tuberculosis Treatment https://ClinicalTrials.gov/show/NCT00419068 Completed Barts & The London NHS Trust 2009-09-30
NCT00401271 Safety, Efficacy and Pharmacokinetics of OPC-67683 in Patients With Pulmonary Tuberculosis https://ClinicalTrials.gov/show/NCT00401271 Completed Otsuka Frankfurt Research Institute GmbH NA
NCT00396084 Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis https://ClinicalTrials.gov/show/NCT00396084 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2007-11-23
NCT00366470 A Clinical Trial to Study the Effect of the Addition of Vitamin D to Conventional Treatment in New Pulmonary Tuberculosis Patients https://ClinicalTrials.gov/show/NCT00366470 Completed Christian Medical College, Vellore, India 2012-05-31
NCT00341328 Efficacy and Safety of Immunomodulator as an Adjunct Therapy in New Pulmonary Tuberculosis(Category I) Patients. https://ClinicalTrials.gov/show/NCT00341328 Completed Ministry of Science and Technology, India 2011-10-31
NCT00311298 Nutrition, Diabetes and Pulmonary TB/HIV https://ClinicalTrials.gov/show/NCT00311298 Completed University of Copenhagen 2009-03-31
NCT00298870 Randomized Trial for Pharmacogenomics-based Tuberculosis Therapy (RT-PGTT) https://ClinicalTrials.gov/show/NCT00298870 Completed Osaka University NA
NCT00265226 Efficacy and Safety Study of Immunomodulator as an Adjunct Therapy in Pulmonary Tuberculosis (TB) Retreatment Patients https://ClinicalTrials.gov/show/NCT00265226 Completed Ministry of Science and Technology, India 2010-12-31
NCT00140309 TBTC Study 27: Moxifloxacin vs Ethambutol for TB Treatment https://ClinicalTrials.gov/show/NCT00140309 Completed Centers for Disease Control and Prevention NA
NCT00057434 Vitamin A Therapy for Tuberculosis https://ClinicalTrials.gov/show/NCT00057434 Completed National Institute of Allergy and Infectious Diseases (NIAID) NA
NCT00023335 TBTC Study 22: Efficacy of Once-Weekly Rifapentine and Isoniazid in Treatment of Tuberculosis https://ClinicalTrials.gov/show/NCT00023335 Completed Centers for Disease Control and Prevention NA
NCT00000796 A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients. https://ClinicalTrials.gov/show/NCT00000796 Completed National Institute of Allergy and Infectious Diseases (NIAID) NA
NCT00000778 A Pilot Study of Methodology to Rapidly Evaluate Drugs for Bactericidal Activity, Tolerance, and Pharmacokinetics in the Treatment of Pulmonary Tuberculosis Using Isoniazid and Levofloxacin https://ClinicalTrials.gov/show/NCT00000778 Completed National Institute of Allergy and Infectious Diseases (NIAID) NA
NCT00001407 Interferon Gamma for Drug Resistant Tuberculosis https://ClinicalTrials.gov/show/NCT00001407 Completed National Institutes of Health Clinical Center (CC) NA
NCT00004444 Pilot Randomized Study of Paromomycin (Aminosidine) vs Streptomycin for Uncomplicated Pulmonary Tuberculosis https://ClinicalTrials.gov/show/NCT00004444 Completed FDA Office of Orphan Products Development NA

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT03072576 Accuracy and Feasibility of Xpert Ultra https://ClinicalTrials.gov/show/NCT03072576 Completed Foundation for Innovative New Diagnostics, Switzerland 2017-03-31
NCT02984579 Line Probe Assay Evaluation Study https://ClinicalTrials.gov/show/NCT02984579 Completed Foundation for Innovative New Diagnostics, Switzerland 2016-01-31
NCT02758236 Tuberculosis Research of INA-RESPOND On Drug Resistance https://ClinicalTrials.gov/show/NCT02758236 Active, not recruiting Ina-Respond 2021-12-31
NCT02736864 Structural and Functional Repercussions of Pulmonary Tuberculosis Sequelae https://ClinicalTrials.gov/show/NCT02736864 Completed Federal University of Uberlandia 2017-10-31
NCT02653404 IGRA and Mantoux Response in Children With Suspected Latent or Active TB Infection https://ClinicalTrials.gov/show/NCT02653404 Recruiting University of Siena 2019-04-30
NCT02382107 A Blinded, Cross-sectional, Diagnostic Evaluation Study Performed in Pulmonary TB Suspects at the TB Dispensary for Sector 4 of the Marius-Nasta-Institute in Bucharest, Romania https://ClinicalTrials.gov/show/NCT02382107 Completed Ludwig-Maximilians - University of Munich 2016-05-31
NCT01301144 Oral Urea Breath Testing for Diagnosis and Treatment Response in Pulmonary Tuberculosis https://ClinicalTrials.gov/show/NCT01301144 Completed National Institutes of Health Clinical Center (CC) NA
NCT01866579 Early Retinal Nerve Fiber Layer Change of Ethambutol Optic Neuropathy by Optical Coherence Tomography https://ClinicalTrials.gov/show/NCT01866579 Completed Yonsei University 2014-05-31
NCT03350048 Evaluation of Host Biomarker-based Point-of-care Tests for Targeted Screening for Active TB https://ClinicalTrials.gov/show/NCT03350048 Enrolling by invitation University of Stellenbosch 2019-06-30
NCT01587469 Evaluation of Xpert MTB/RIF Assay for the Rapid Identification of TB and TB Rifampin Resistance in Pulmonary Tuberculosis Suspects https://ClinicalTrials.gov/show/NCT01587469 Completed Cepheid 2014-02-21
NCT01364324 Pharmacokinetics of Anti-tuberculosis Drugs in Gastrectomized Patients https://ClinicalTrials.gov/show/NCT01364324 Recruiting National Cancer Center, Korea 2020-06-30
NCT04434976 Delayed Diagnosis of Bacteriologically Positive Pulmonary Tuberculosis and Relative Optimized Suggestions in China https://ClinicalTrials.gov/show/NCT04434976 Completed Huashan Hospital 2019-11-02
NCT04342598 Case Control Study of Vitamin D Status and Adult Multidrug-resistant Pulmonary Tuberculosis in Maharashtra, India https://ClinicalTrials.gov/show/NCT04342598 Recruiting Harvard School of Public Health 2020-09-30
NCT03728725 Xpert MTB/XDR Clinical Evaluation Trial https://ClinicalTrials.gov/show/NCT03728725 Recruiting Foundation for Innovative New Diagnostics, Switzerland 2020-07-31
NCT03712709 Clinical Evaluation of the Truenat Point-of-care Tuberculosis Diagnostic Test https://ClinicalTrials.gov/show/NCT03712709 Recruiting Foundation for Innovative New Diagnostics, Switzerland 2019-09-30
NCT01002170 Pharmacokinetic Study of Patients Who Undergo Cycloserine, a 2nd-line Antituberculosis Medicament https://ClinicalTrials.gov/show/NCT01002170 Completed Taipei Medical University WanFang Hospital 2009-06-30
NCT00834353 Prospective Study of N-acetyltransferase2 (NAT2) and Cytochrome P4502E1 (CYP2E1) Gene as Susceptible Risk Factors for Antituberculosis (ATT) Induced Hepatitis https://ClinicalTrials.gov/show/NCT00834353 Completed Maulana Azad Medical College 2008-03-31
NCT01379066 Tuberculosis Volatile Organic Compounds https://ClinicalTrials.gov/show/NCT01379066 Completed Landon Pediatric Foundation 2009-12-31
NCT00803322 Improving Community Based Tuberculosis Care in Ethiopia https://ClinicalTrials.gov/show/NCT00803322 Completed University of Bergen 2007-09-30
NCT03271567 Nanodisk-MS Assay for the Diagnosis of Active Pulmonary and Extrapulmonary Tuberculosis in Hospitalized Patients https://ClinicalTrials.gov/show/NCT03271567 Completed Chinese University of Hong Kong 2019-07-31
NCT00772408 Toll-like Receptor 2 Gene Polymorphism, Serum Cytokines and Susceptibility to Disease Severity or Treatment Response of Pulmonary Tuberculosis https://ClinicalTrials.gov/show/NCT00772408 Completed Chang Gung Memorial Hospital 2009-11-30
NCT00567151 Co-Infection of NTM in Patients With Smear Positive Pulmonary TB https://ClinicalTrials.gov/show/NCT00567151 Completed Seoul National University Hospital 2008-12-31
NCT00212550 Evaluation of the Practice of Three Morning Sputa on Separate Days for Diagnosis of Mtb https://ClinicalTrials.gov/show/NCT00212550 Completed NYU Langone Health 2010-02-28
NCT00054769 Diagnosing Tuberculosis in HIV Infected Children in Peru https://ClinicalTrials.gov/show/NCT00054769 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2007-02-28

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT03251196 TB Sequel: Pathogenesis and Risk Factors of Long-term Sequelae of Pulmonary TB https://ClinicalTrials.gov/show/NCT03251196 Recruiting The Aurum Institute NPC 2022-06-30
NCT02715271 Study of TB Lesions Obtained in Therapeutical Surgery https://ClinicalTrials.gov/show/NCT02715271 Active, not recruiting Fundació Institut Germans Trias i Pujol 2020-07-31
NCT02527486 Seoul National University Airway Registry https://ClinicalTrials.gov/show/NCT02527486 Recruiting Seoul National University Hospital 2021-12-31
NCT02331056 Could the Stroke Volume Variation Predict a Fluid Responsiveness in Thoracotomy? https://ClinicalTrials.gov/show/NCT02331056 Completed Samsung Medical Center 2015-06-30
NCT04236349 Tuberculosis Cohort in the North of Paris https://ClinicalTrials.gov/show/NCT04236349 Recruiting Assistance Publique - Hôpitaux de Paris 2020-01-31
NCT04079400 Microbiome in Pulmonary Tuberculosis, Non-tuberculous Mycobacterial Pulmonary Diseases, Lung Cancer and Hemoptysis https://ClinicalTrials.gov/show/NCT04079400 Completed Gachon University Gil Medical Center 2018-10-30
NCT04074369 Evaluation of CRISPR-based Test for the Rapid Identification of TB in Pulmonary Tuberculosis Suspects https://ClinicalTrials.gov/show/NCT04074369 Recruiting Huashan Hospital 2019-10-30
NCT04055584 PCR Techniques of Dried Sputum Using a Spotcard https://ClinicalTrials.gov/show/NCT04055584 Recruiting University Medical Center Groningen 2020-11-30
NCT03416309 Personalization of AntiTB Treatment: Evaluation of Pharmacological Determinants of Treatment Response https://ClinicalTrials.gov/show/NCT03416309 Recruiting University of Turin, Italy 2021-02-28
NCT03822156 Clinical Analysis of the Patients With Cavitary Pulmonary TB and Endobronchial TB in the PPM-UUH Cohort https://ClinicalTrials.gov/show/NCT03822156 Completed University of Ulsan 2018-06-30